Capricorn Fund Managers Ltd Purchases New Shares in Jazz Pharmaceuticals PLC $JAZZ

Capricorn Fund Managers Ltd acquired a new position in shares of Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) during the 4th quarter, according to its most recent Form 13F filing with the SEC. The firm acquired 10,000 shares of the specialty pharmaceutical company’s stock, valued at approximately $1,700,000.

A number of other institutional investors also recently bought and sold shares of the business. Vestal Point Capital LP acquired a new stake in shares of Jazz Pharmaceuticals during the second quarter worth about $127,344,000. Goldentree Asset Management LP acquired a new position in Jazz Pharmaceuticals in the 3rd quarter valued at about $149,597,000. Schonfeld Strategic Advisors LLC raised its stake in Jazz Pharmaceuticals by 592.1% during the 3rd quarter. Schonfeld Strategic Advisors LLC now owns 436,443 shares of the specialty pharmaceutical company’s stock valued at $57,523,000 after acquiring an additional 373,383 shares during the last quarter. AQR Capital Management LLC lifted its position in Jazz Pharmaceuticals by 62.1% during the 2nd quarter. AQR Capital Management LLC now owns 794,770 shares of the specialty pharmaceutical company’s stock worth $84,341,000 after acquiring an additional 304,463 shares during the period. Finally, Dimensional Fund Advisors LP grew its stake in shares of Jazz Pharmaceuticals by 11.8% in the 3rd quarter. Dimensional Fund Advisors LP now owns 2,836,652 shares of the specialty pharmaceutical company’s stock valued at $373,855,000 after purchasing an additional 298,815 shares during the last quarter. 89.14% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several equities research analysts have recently commented on the company. Weiss Ratings restated a “sell (d+)” rating on shares of Jazz Pharmaceuticals in a research note on Friday, March 27th. Piper Sandler lifted their price objective on shares of Jazz Pharmaceuticals from $219.00 to $232.00 and gave the company an “overweight” rating in a research report on Thursday, March 19th. Needham & Company LLC upped their price objective on shares of Jazz Pharmaceuticals from $210.00 to $235.00 and gave the stock a “buy” rating in a research report on Monday, January 12th. Morgan Stanley raised their target price on shares of Jazz Pharmaceuticals from $225.00 to $226.00 and gave the stock an “overweight” rating in a research note on Wednesday, February 25th. Finally, Wells Fargo & Company lifted their target price on shares of Jazz Pharmaceuticals from $235.00 to $250.00 and gave the company an “overweight” rating in a report on Wednesday, February 25th. One research analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $215.38.

Jazz Pharmaceuticals Price Performance

Jazz Pharmaceuticals stock opened at $186.95 on Monday. The company has a debt-to-equity ratio of 1.00, a current ratio of 1.86 and a quick ratio of 1.67. Jazz Pharmaceuticals PLC has a 1-year low of $95.49 and a 1-year high of $198.00. The company has a market cap of $11.51 billion, a PE ratio of -31.31, a price-to-earnings-growth ratio of 0.33 and a beta of 0.23. The stock’s 50 day moving average price is $177.39 and its 200 day moving average price is $162.39.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last announced its quarterly earnings data on Wednesday, February 25th. The specialty pharmaceutical company reported $6.64 earnings per share for the quarter, topping analysts’ consensus estimates of $6.49 by $0.15. Jazz Pharmaceuticals had a positive return on equity of 6.87% and a negative net margin of 8.35%.The firm had revenue of $1.20 billion for the quarter, compared to analyst estimates of $1.17 billion. During the same quarter in the prior year, the company posted $6.51 earnings per share. Jazz Pharmaceuticals’s quarterly revenue was up 8.1% on a year-over-year basis. On average, sell-side analysts predict that Jazz Pharmaceuticals PLC will post 16.96 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, SVP Mary Elizabeth Henderson sold 5,343 shares of the firm’s stock in a transaction dated Thursday, February 26th. The shares were sold at an average price of $194.49, for a total value of $1,039,160.07. Following the completion of the sale, the senior vice president owned 28,728 shares in the company, valued at $5,587,308.72. This trade represents a 15.68% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Bruce C. Cozadd sold 6,000 shares of the business’s stock in a transaction dated Wednesday, April 1st. The stock was sold at an average price of $190.50, for a total transaction of $1,143,000.00. Following the sale, the director directly owned 384,682 shares in the company, valued at approximately $73,281,921. This represents a 1.54% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders have sold 74,015 shares of company stock worth $14,180,486. Insiders own 4.30% of the company’s stock.

Jazz Pharmaceuticals Profile

Jazz Pharmaceuticals plc is a global biopharmaceutical company focused on developing and commercializing therapies in neuroscience and oncology. The company’s research and development efforts target unmet medical needs in sleep disorders, hematologic malignancies, rare neurological conditions and solid tumors. Jazz’s product portfolio includes therapies for narcolepsy, hepatic veno-occlusive disease, acute myeloid leukemia and other serious disorders.

Flagship products from Jazz Pharmaceuticals include Xyrem® (sodium oxybate) and Xywav® (calcium, magnesium, potassium, and sodium oxybates) for the treatment of cataplexy and excessive daytime sleepiness in patients with narcolepsy.